Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
14G6
- Development stage
- Unknown
- Lead developer
- The Walter & Eliza Hall Institute of Medical Research (WEHI)
- Modality
- Antibody-Based Therapeutics
01
Overview
14G6: sourced facts only. name: "We used mouse B cell cloning to identify 14G6, the first antibody that is specific for the non-activated, monomeric BAK conformation." [DOI:10.1158/1538-7445.am2025-1382]; target: "We used mouse B cell cloning to identify 14G6, the first antibody that is specific for the non-activated, monomeric BAK conformation." [DOI:10.1158/1538-7445.am2025-1382]; developer: "The Walter & Eliza Hall Institute of Medical Research (WEHI), Parkville, Australia." [DOI:10.1158/1538-7445.am2025-1382]; modality: "We used mouse B cell cloning to identify 14G6, the first antibody that is specific for the non-activated, monomeric BAK conformation." [DOI:10.1158/1538-7445.am2025-1382]
02
Targets
BAK
Beyond the preview
Go deeper on 14G6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 14G6.